Oncogene:调控回路HP1γ/miR-451a/c-Myc可以促进前列腺癌恶化

2017-10-10 AlexYang MedSci原创

有研究已经表明异染色质蛋白1γ(HP1γ)在各种癌症类型中具有致癌作用。然而,HP1γ在前列腺癌(PCa)恶化中的角色和潜在的分子机制仍旧有很多未知。最近,有研究人员发现HP1γ在前列腺癌中表达上调,并且HP1γ在前列腺癌中的水平有所提高,这也可以预测不良的治疗结果。另外,HP1γ蛋白在前列腺癌细胞中的缺失不仅抑制的癌细胞的增殖和诱导细胞凋亡,还可以一定程度的组织致瘤性。研究人员还发现了c-Myc

有研究已经表明异染色质蛋白1γ(HP1γ)在各种癌症类型中具有致癌作用。然而,HP1γ在前列腺癌(PCa)恶化中的角色和潜在的分子机制仍旧有很多未知。

最近,有研究人员发现HP1γ在前列腺癌中表达上调,并且HP1γ在前列腺癌中的水平有所提高,这也可以预测不良的治疗结果。另外,HP1γ蛋白在前列腺癌细胞中的缺失不仅抑制的癌细胞的增殖和诱导细胞凋亡,还可以一定程度的组织致瘤性。研究人员还发现了c-Myc可以通过直接结合到HP1γ基因第一个内含子的E-box元件,能够上调HP1γ蛋白的表达,并且上调的HP1γ蛋白表达反过来可以通过增加miR-451a启动子区域的H3K9甲基化来抑制miR-451a的表达。更进一步的是,miR-451a的减少可以显著的逆转HP1γ丧失诱导的PCa细胞凋亡,然而,miR-451a的超表达可以通过定向下调c-Myc的表达来抑制细胞生存。另外,c-Myc、HP1γ和miR-451a的相关关系在人类临床样本中得到了进一步的确定。最后,研究人员指出,HP1γ/miR-451a/c-Myc回路在PCa细胞中存在并且该回路对PCa恶化具有重要作用。

原始出处:

C Chang, J Liu, W He et al. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression. Oncogene. 2 Oct 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-12-09 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-09-10 smallant2002
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 guihongzh
  6. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 lixiaol
  7. [GetPortalCommentsPageByObjectIdResponse(id=2048912, encodeId=25d02048912d9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 09 15:59:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068720, encodeId=b9ce2068e2007, content=<a href='/topic/show?id=352f905513' target=_blank style='color:#2F92EE;'>#HP1γ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9055, encryptionId=352f905513, topicName=HP1γ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Aug 27 21:59:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813318, encodeId=2fa2181331895, content=<a href='/topic/show?id=3d259200506' target=_blank style='color:#2F92EE;'>#调控回路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92005, encryptionId=3d259200506, topicName=调控回路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Mon Aug 13 13:59:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930523, encodeId=edf41930523e9, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Sep 10 20:59:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274803, encodeId=ff5f12e480390, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530298, encodeId=b9111530298dd, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558090, encodeId=091b155809004, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Oct 12 12:59:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 zsyan

相关资讯

J Patient Exp:前列腺癌病人中护士主导的电话服务模式

医疗健康成本的不断增加促使了人们对更加有效的利用和分配医疗资源进行重新的思考。护士主导的PSA电话跟踪服务也许为降低医疗健康成本提供了一个合适的选择。最近,有研究人员招募了815名病人,并参与了护士主导的稳定的前列腺癌电话跟踪服务。研究人员选择了一个方便的样本用来进行邮递形式的问卷调查评估,主要评估内容是病人的满意度。研究中的815名病人在为期10年的跟踪服务中电话次数高达3683次。大多数病人对

Eur Urol :17-基因GPS可更好的为前列腺癌患者进行分层和判断预后。

许多前列腺癌生长较为缓慢,往往不会扩散或威胁患者的生命,而另一些则更具侵略性,需要及时治疗。越来越多的医生正在使用新的分子测试来辨别前列腺癌的侵袭性,以更准确的制定出治疗策略。

BJU Int:病人对局部前列腺癌治疗相关风险观点的准确性分析

最近,有研究人员评估了局部前列腺癌(PC)病人对根治性前列腺癌切除术(RP)、放射疗法(RT)和积极检测(AS)治疗结果和风险的理解,并鉴定了相关的误解。研究人员利用426名新诊断为局部PC的病人的基线数据(在提供治疗信息之前完成调查问卷,并且在治疗之前进行)进行分析研究。该研究是一个前瞻性的、纵向性的和多中心的研究。研究人员对病人在治疗前对治疗方法副作用观点的差异与基于文献资料的数据进行了比较,

Rev Urol:高血压与前列腺癌的相关性分析

2016年的一份元分析表述了高血压与前列腺癌可能的联系。最近,有研究人员回顾性的评估了年龄在51岁到76岁的3200名前列腺癌病人中高血压的发生频率。数据集中在年龄、种族(非裔美国人和白人)、高血压、糖尿病和身体质量指数(BMI)。病人按照年龄分成三个小组:即51岁到60岁、61岁到70岁和71到76岁。研究群体包括了1388名非裔美国人(43%)和1812名白种人(57%)。研究人员在1013(

BMC Med:男人身高愈高,死于前列腺癌的风险也愈高

身高是许多女性选择男友的重要条件之一,据说 178 公分是多数女性心中男友的理想身高。个子高的男人给人一种安全感,站在他身边有一种小鸟依人的幸福感。个子高当然也有缺点,例如看电影座位太挤、买衣服选择较少等。英国最近的研究更显示,高个子的男性罹患“恶性”前列腺癌而死亡的机率较高。

Food Chem: 蜂蜜对前列腺癌细胞具有毒性且与MTT反应物互作

蜂蜜是一种复杂的生物物质,包含有许多的糖类、酚类复合物和酶类。最近,有研究人员利用5种快速的和可检测的实验来测量蜂蜜体外细胞毒性。研究发现,蜂蜜对前列腺癌细胞PC3和DU145具有细胞学毒性。然而,细胞死亡的水平在不同试验中水平不同。MTT试验容易被MTT反应物的减少而影响,并且蜂蜜减少的糖类和酚类物质容易使得MTT试验结果不同。乳酸脱氢酶试验容易因蜂蜜氧化酵素辅助因子NADH而使得试验无效。磺酰